Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Insulin prices

- PMLiVE

Sanofi and Sobi’s efanesoctocog alfa granted FDA priority review for haemophilia A

Phase 3 results showed once-weekly doses provided clinically meaningful bleed protection for patients with haemophilia A

- PMLiVE

Novo Nordisk announces positive phase 2 trial results for type 2 diabetes treatment

More than 4.9 million people in the UK have diabetes, around 90% of which have type 2 diabetes

- PMLiVE

Sanofi and NIHR enrol first patient in immunisation study for RSV in infants

RSV is the leading global cause of infant hospitalisation and affects 90% of children under the age of two

- PMLiVE

Sanofi halts recruitment for trials assessing MS treatment

The pause in enrolment follows advice issued by the Independent Data Monitoring Committee

- PMLiVE

Sanofi and Innovent Biologics to develop oncology drugs for patients in China

Sanofi will make an initial equity investment of €300m in Innovent

- PMLiVE

Eli Lilly to make bebtelovimab commercially available to US states from August

The COVID-19 antibody is expected to become commercially available prior to the anticipated depletion of the US government’s current available supply

- PMLiVE

Sanofi and Regeneron announce positive phase 3 trial results for eosinophilic oesophagi in children under 12

There are currently no approved treatments for children with eosinophilic oesophagi under the age of 12

- PMLiVE

Sanofi and Sobi announce positive phase 3 trial results for severe haemophilia A

Results from the study showed once-weekly efanesoctocog alfa doses provided ‘clinically meaningful’ bleed protection for patients with severe haemophilia A

- PMLiVE

Novo Nordisk announces positive phase 3 results for haemophilia treatment

Haemophilia affects around 1,125,000 people globally

- PMLiVE

Sanofi Global Health unveils new nonprofit Impact brand

The brand will enable 30 Sanofi medicines to be distributed to 40 low-income countries

- PMLiVE

Eli Lilly to supply US government with 150,000 additional doses of bebtelovimab

The antibody drug treatment has thus far only been authorised for emergency use by the FDA to treat COVID-19 in specific emergency cases in non-hospital settings

- PMLiVE

Sanofi and GSK report positive data for COVID-19 Beta vaccine

Results from stage 1 and stage 2 of the study showed a favourable safety and tolerability profile

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links